Vaccination against infectious disease is hailed as one of the great achievements in public health. However, the United States Recommended Childhood Immunization Schedule is becoming increasingly complex as it is expanded to cover additional diseases. Moreover, biotechnology advances have allowed vaccine manufacturers to create combination vaccines that immunize against several diseases in a single injection. All these factors are creating a combinatorial explosion of alternatives and choices (each with a different cost) for public health policy makers, pediatricians, and parents/guardians (each with a different perspective). The General Vaccine Formulary Selection Problem (GVFSP) is introduced to model general childhood immunization schedules that can be used to illuminate these alternatives and choices by selecting a vaccine formulary that minimizes the cost of fully immunizing a child and the amount of extraimmunization. Both exact algorithms and heuristics for GVFSP are presented. A computational comparison of these algorithms and heuristics is presented for the 2006 Recommended Childhood Immunization Schedule, as well as several randomly generated childhood immunization schedules that are likely to be representative of future childhood immunization schedules. The results reported here provide both fundamental insights into the structure of the GVFSP models and algorithms and practical value for the public health community.
Motivation and Introduction
The Centers for Disease Control and Prevention (CDC) is the federal agency responsible for overseeing pediatric immunization practice and policy in the United States. Each year, based on recommendations from the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP), the CDC publishes a Recommended Childhood Immunization Schedule that outlines vaccination requirements for children through adolescence (CDC 2006a; see Figure 1 for the 2006 schedule). The Recommended Childhood Immunization Schedule indicates the vaccinations required to protect a child against several (currently 13) infectious diseases that pose a risk to children living in the United States (see Appendix 1 for a discussion on infectious diseases and their impact on public health). This schedule includes the number of required doses of each vaccine and the recommended age for each dose. For example, polio requires four vaccine doses, where the third dose may be administered at age 6 months, 12 months, 15 months, or 18 months.
Each vaccine dose is typically administered by injection during a scheduled wellness check-up at a health care clinic. For example, an infant child should receive a vaccine dose for hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae type b, polio, and pneumococcus at their two-month wellness check-up. Using currently licensed vaccines, this child might have as many as five injections administered during this particular checkup. A 15-month old child, under extreme conditions, might have as many as eight injections administered in a single clinic visit. Clearly, the Recommended Childhood Immunization Schedule has become overly crowded and complex and is likely to expand in the future as new infectious diseases emerge and new vaccines are developed. One consequence of these complexities is an increase in the likelihood that a parent/guardian will reject or delay some vaccinations. The cost of vaccinating a child also contributes to the underimmunization of children-the opportunity cost of time for a parent/guardian to make clinic visits as well as the monetary cost of vaccination (Plotkin and Orenstein 2004) . These costs often contribute to either missed clinic visits or missed vaccine doses. For example, the three-year measles epidemic in the United States (that began in 1990) involved 28,000 cases of measles, most of which were due to inadequate vaccination of these patients when they were one to two years of age (Mackay and Rosen 2001) . Clearly, noncompliance with the Recommended Childhood Immunization Schedule puts children at risk of contracting potentially debilitating (and sometimes fatal) infectious diseases, thereby creating an enormous cost burden (both tangible and intangible) on the individual child, family, and society at large. For example, the CDC's 2005 National Immunization Survey estimates a savings of US $27 in direct and indirect costs for every dollar spent on vaccinating against diphtheria, tetanus, and pertussis (Cochi 2005) . Weniger (1996) discusses several options that address the issues of vaccine injection overcrowding, schedule complexity, and the cost of vaccinating a child. The most feasible option is the development and use of combination vaccines-a vaccine that combines several antigens (a substance that stimulates the production of an antibody, e.g., toxins, bacteria, foreign blood cells, and the cells of transplanted organs) into a single injection. Some combination vaccines are already commonly used, such as the DTaP vaccine, which combines diphtheria and tetanus toxoids with acellular pertussis vaccine. The ideal combination vaccine would combine antigens for every disease in the Recommended Childhood Immunization Schedule into a single vaccine, which could be administered at birth. However, developing such a vaccine is highly unlikely, based on financial and biological constraints. For example, live vaccines (vaccines that inject living antigens) can interfere with each other by competing for antibody binding sites (although multiple injections of live vaccines are permissible provided they are at different anatomic sites (CDC 2006b) ). Nonetheless, several pediatric combination vaccines are now coming to market, and several more are being developed and tested for licensure in the United States (Infectious Diseases in Children 2002) . For example, Proquad ® , a combination vaccine manufactured by Merck that immunizes against measles, mumps, rubella, and varicella, gained Food and Drug Administration (FDA) approval in September 2005. Combination vaccines will alleviate the issue of vaccine injection overcrowding and also offer economic opportunities by being more affordable per dose and reducing the shipping, handling, and storage costs of vaccines (Edwards and Decker 2001) . However, combination vaccines also offer pediatricians, public health policy makers, and parents/guardians more choices on how to best immunize a child and, hence, increase the schedule complexity. In fact, as the Recommended Childhood Immunization Schedule continually evolves, new combination vaccines will lead to a combinatorial explosion of alternatives and choices, each with a different cost and benefit. Therefore, a model to address the economic issue of cost in selecting appropriate pediatric vaccines for immunization is one focus of this research.
Given the growth of combination vaccines and the overcrowding of the Recommended Childhood Immunization Schedule, the medical issue of extraimmunization has begun to draw more attention from both medical and public health personnel. Extraimmunization means that a child receives antigens for a given disease over the recommended quantity and timing sequence. Because combination vaccines reduce the number of required injections, pediatricians, public health policy makers and administrators, and parents/guardians will likely choose combination vaccines over multiple single-antigen vaccines. However, using combination vaccines might result in a child being injected with antigens that they have already received in the recommended quantity and timing sequence. For example, injecting a child with Pediarix ® (the DTaP-HBV-IPV (diphtheria, tetanus, pertussis, hepatitis B, and polio) combination vaccine) at age 4 months would provide extraimmunization for hepatitis B because no dose of vaccine is required at that age (see Figure 1 ). Such extraimmunization poses biological risks and amplifies philosophical concerns (Edwards and Decker 2001) .
Biologically, extraimmunization of some antigens increases the risk of adverse side effects. Such is the case with diphtheria and tetanus vaccines (CDC 1999) . Philosophically, many people challenge the safety and effectiveness of vaccinating children and particularly object to the use of combination vaccines because they believe that injecting a child with multiple antigens simultaneously overwhelms the infant immune system, and hence extraimmunization due to combination vaccines only increases these fears (Edwards and Decker 2001, Chen et al. 2001 ). This philosophical barrier to vaccination is an increasing concern for pediatricians and public health administrators. Therefore, a model to address the medical issue of extraimmunization is also of value to the public health community and provides a second focus for this research.
Operations research methodologies have been applied to address pediatric immunization problems. Most of this research addresses the economics of pediatric immunization, combination vaccine pricing, and vaccine wastage (Jacobson et al. 2003a . Weniger et al. (1998) report the results of a pilot study that uses operations research methods in assessing the economic value of vaccine formularies (i.e., the set of vaccines inventoried by an immunization clinic or pediatrician). Specifically, the Recommended Childhood Immunization Schedule for a subset of diseases (diphtheria, tetanus, pertussis, Haemophilus influenzae type b, and hepatitis B) and a reduced set of time periods (1 month, 2 months, 4 months, 6 months, 12-18 months, and 60 months) were modeled as an integer program (IP). The objective of this IP model was to aid decision makers in determining the vaccine formulary that minimized the cost to fully immunize a child against all five diseases. They describe how the model might be used to determine the "best value" to vaccine purchasers and briefly describe how operations research models might help evaluate the economic value of vaccines being researched and developed. Jacobson et al. (1999) present a rigorous presentation of this pilot study and demonstrate how the model selects different vaccine formularies depending on the desired economic criteria. Sewell et al. (2001) embed the IP from the pilot study into a bisection algorithm (Burden and Faires 1997) to "reverse engineer" the maximum inclusion prices (i.e., the maximum price at which a vaccine remains part of the optimal vaccine formulary) of four combination vaccines not yet licensed (at that time) in the United States. Sewell and Jacobson (2003) present a rigorous description of this study, including the complete IP model formulation. This paper also demonstrates how operations research can provide an economic analysis tool for pharmaceutical companies that develop and manufacture vaccines. For additional applications of this bisection algorithm, see Jacobson et al. (2003b Jacobson et al. ( , 2005 . Jacobson and Sewell (2002) extend the bisection/IP algorithm by including it with Monte Carlo simulation, thereby determining a probability distribution for the price of the four potential combination vaccines. Hall et al. (2008) is the first paper to address the issue of extraimmunization by presenting a model that maximizes the effectiveness of a given vaccine formulary while strictly prohibiting extraimmunization.
Although the economic issue of minimizing cost and the medical issue of minimizing extraimmunization in pediatric immunization are fundamentally separate objectives, they can be combined into a single model. This paper extends the research described above by defining the General Vaccine Formulary Selection Problem (GVFSP) IP model, which minimizes a weighted sum of the cost to fully immunize a child and the amount of extraimmunization. Considering the economic issue and extraimmunization separately, special cases of GVFSP are also discussed, denoted as the General Minimum Cost Vaccine Formulary Selection Problem (GMCVFSP) and the General Limited Extraimmunization Vaccine Formulary Selection Problem (GLEVFSP), respectively. GVFSP generalizes previous IP models reported in the literature by capturing any generic childhood immunization schedule. A computational complexity analysis of the GVFSP is given, including an identification of both intractable and polynomial solvable special cases. An exact DP algorithm as well as heuristics for the GVFSP is presented. An extensive computational study is presented, based on current and future childhood immunization schedules.
This paper is organized as follows. Section 2 presents general model formulations for the discrete optimization problem GVFSP that determine the set of vaccines (i.e., a vaccine formulary) that should be used in a clinical environment to satisfy any given childhood immunization schedule. Terminology, assumptions, and special cases (GMCVFSP and GLEVFSP) are also presented in §2. Section 3 presents the computational complexity of GVFSP. Section 4 presents a description and analysis of several algorithms, both exact and heuristics, for solving GVFSP. Using GMCVFSP, §5 presents a computational comparison of these algorithms for the 2006 Recommended Childhood Immunization Schedule and several randomly generated childhood immunization schedules that are likely to be representative of future childhood immunization schedules. Section 6 discusses additional solution methodologies for GVFSP and computationally examines the trade-off between the two objectives of cost and extraimmunization. Section 7 presents conclusions and future directions of research.
Model Formulation and Terminology
This section presents the model formulations for the GVFSP discrete optimization problem used to design a vaccine formulary for a given childhood immunization schedule and discusses two special cases (GMCVFSP and GLEVFSP), each focusing on a separate issue. GVFSP determines the set of vaccines (i.e., vaccine formulary) that should be used in a clinical environment to satisfy a given childhood immunization schedule, such that a weighted sum of the cost to fully immunize a child and the amount of extraimmunization is minimized. GMCVFSP determines the set of vaccines that should be used in a clinical environment to satisfy a given childhood immunization schedule at minimum cost, and hence is a special case of GVFSP that focuses on the economic issue of minimizing cost. Similarly, GLEVFSP determines the set of vaccines that should be used in a clinical environment to satisfy a given childhood immunization schedule while minimizing the amount of extraimmunization, and hence is a special case of GVFSP that focuses on the medical issue of extraimmunization. To precisely describe a childhood immunization schedule, several sets and parameter definitions are needed. Let T = 1 2 : set of time periods for a given childhood immunization schedule. D = 1 2 : set of diseases requiring immunization. V = 1 2 : set of vaccines available to immunize against the diseases in D.
n d ∈ Z + : number of vaccine doses that must be admin-
K v ∈ Q + : cost (in terms of economic cost and extraimmunization cost) of vaccine v ∈ V .
I vd = 1 if vaccine v ∈ V immunizes against disease d ∈ D, 0 otherwise (a set of binary parameters that indicate which vaccines immunize against which diseases).
P djt = 1 if in time period t ∈ T , a vaccine may be administered to satisfy the jth dose requirement for disease d ∈ D, j = 1 2 n d , 0 otherwise (a set of binary parameters that indicate the set of time periods during which a particular vaccine dose could be administered to immunize against a disease).
These sets and parameters capture any arbitrary childhood immunization schedule together with a set of vaccines and vaccine cost information. Unless otherwise stated, the phrase "childhood immunization schedule" refers to an arbitrary general immunization schedule, whereas the phrase "Recommended Childhood Immunization Schedule" refers to the published CDC immunization schedule (see Figure 1) . Figure 1 ), m 1 = 1 1 2 2 2 2 2 3 3 3 and M 1 = 1 2 2 2 3 3 3 3 3 3 , and hence
Finally, the cost parameter, c v , quantifies the economic cost of vaccine v ∈ V . For example, Weniger et al. (1998) define the economic cost of a vaccine as the sum of the actual vaccine purchase price, the cost of preparing the vaccine by medical staff, and the cost of administration (needle/syringe, needle-free injections, or oral), whereas K v captures the economic cost and extraimmunization cost for vaccine v ∈ V .
These parameters provide a robust framework for describing a childhood immunization schedule and for defining additional terminology. For example, in Figure 1 , influenza requires a yearly dose of vaccine. This dose schedule is captured by inserting time periods into the childhood immunization schedule and then using scheduling parameters P djt to indicate the yearly requirement. Therefore, in Figure 1 , time period 10 = 4-6 yrs can be replaced by time periods 10 = 36 months, 11 = 48 months, 12 = 60 months, and 13 = 72 months, and hence dose 1 for Influenza is permitted in time period 5, 6, 7, or 8; and dose 2, 3, 4, 5, and 6 is permitted in time period 9, 10, 11, 12, and 13, respectively, which is enforced using the binary P djt parameters. The other diseases (diphtheria, tetanus, pertussis, polio, measles, mumps, rubella) that require a dose of vaccine at age 4-6 years can receive this vaccine dose in time period 11, 12, or 13.
Define T dj = t ∈ T P djt = 1 as the time window for disease d ∈ D and vaccine dose j = 1 2 n d , which is the set of time periods when vaccine dose j = 1 2 n d may be administered for disease d ∈ D. Unless otherwise stated, assume that for all diseases d ∈ D and vaccine doses j = 1 2 n d , the time periods in T dj are consecutive. Furthermore, the vaccine doses for all diseases d ∈ D are assumed to be sequentially ordered (i.e., for all vaccine doses j k = 1 2 n d , j < k, there exists a time period t ∈ T such that P djt = 1 and P dkt = 0 for all t t , t ∈ T ). Moreover, extraimmunization for disease d ∈ D is defined as the number of vaccine doses administered beyond dose requirement n d (i.e., t∈T v∈V X tv I vd − n d ).
To present the discrete optimization models, define the following two types of decision variables:
U dt = number of required doses of vaccine that have been administered for disease d ∈ D through time period t ∈ T .
Operations Research 56(6), pp. 1348 pp. -1365 pp. , © 2008 The discrete optimization problem that determines the vaccine formulary that should be used in a clinical environment to satisfy a given childhood immunization schedule, such that a weighted sum of the cost to fully immunize a child and the amount of extraimmunization is minimized, can be formulated as an integer program in the following way:
where Constraint (1) ensures that at most one dose requirement is satisfied for disease d ∈ D in time period t ∈ T (which means that two different dose requirements cannot be satisfied during the same time period). Constraint (2) ensures that the number of required doses for disease d ∈ D may not increase from time period t − 1 ∈ T to time period t ∈ T unless a vaccine that immunizes against disease d ∈ D is administered during time period t ∈ T . Constraint (3) ensures that the number of required doses for disease d ∈ D is between the minimum and maximum dose requirements. These constraints ensure that the total dose requirements in the childhood immunization schedule are satisfied. Finally, constraints (4) and (5) are the binary and integer requirements for each decision variable.
Two special cases of GVFSP exist that are of practical interest. Setting d = 0 for every disease d ∈ D corresponds to the special case GMCVFSP, a discrete optimization problem that determines the vaccine formulary that should be used in a clinical environment to satisfy a given childhood immunization schedule at minimum economic cost (i.e., Minimize t∈T v∈V c v X tv subject to constraints (1) through (5) above). Similarly, setting c v = 0 for every vaccine v ∈ V corresponds to the special case GLEVFSP, a discrete optimization problem that determines the vaccine formulary that should be used in a clinical environment to satisfy a given childhood immunization schedule that minimizes the amount of extraimmunization (i.e., Minimize t∈T v∈V d∈D d I vd X tv subject to constraints (1) through (5) above).
Note that extraimmunization is feasible in GVFSP, and hence GVFSP assumes that the risks of not satisfying the given childhood immunization schedule outweigh the risks associated with extraimmunization. However, because the objective function in GVSFP combines the economic cost with the amount of extraimmunization, the penalty d provides a mechanism to limit the amount of extraimmunization. Therefore, an appropriate value for d likely depends on the risks associated with extraimmunization for dis-
A disadvantage of combining these two separate issues into a single objective function is that it makes it difficult to interpret the resulting optimal solution. Furthermore, solving GVFSP using multiple scalarizations for the trade-off weights will not guarantee a complete characterization of the Pareto efficient frontier because GVFSP is a scalarized nonconvex multiobjective optimization problem (Ehrgott 2005) . Clearly, both special cases of GVFSP (GMCVFSP and GLEVFSP) have objective functions with natural interpretations; however, the appropriateness of these models depends on the intended application. For example, GMCVFSP offers an appropriate model when the risks attributed to extraimmunization are negligible, whereas GLEVSP offers a more appropriate model when the risks attributed to extraimmunization are high. Hall et al. (2008) present a model that strictly prohibits extraimmunization for a given subset of diseases, and hence the solutions for this model might not satisfy the given childhood immunization schedule.
The CDC's documented policy on the use of combination vaccines suggests that extraimmunization is, at present, a secondary concern compared with satisfying the childhood immunization schedule and economic considerations (CDC 1999) . For example, using a combination vaccine that incurs extraimmunization for disease d might be permitted if a vaccine is needed for disease d and the combination vaccine is the only available vaccine that immunizes against disease d , or if a health-care provider (after considering benefits and risks) chooses to use a combination vaccine for the purpose of reducing the number of injections (even if the combination vaccine results in extraimmunization for some disease) (CDC 1999) . Furthermore, CDC (1999) explains that serologically testing a child whose immunity for a specific disease is unknown is often too costly, and hence the child should be treated as unvaccinated, and the appropriate vaccines should be administered (or re-administered). Therefore, extraimmunization is generally allowed if it ensures that vaccination requirements (as outlined in the Recommended Childhood Immunization Schedule) are satisfied, provides an economic benefit, and/or is preferred by the health-care practitioner; that is, extraimmunization is generally accepted by the public health community because it contributes to an overall higher protection rate against infectious disease for the entire population. It is worth noting that current combination vaccines are designed to limit extraimmunization by combining antigens for diseases that have common dose schedules within the Recommended Childhood Immunization Schedule. Moreover, minimizing the economic cost of satisfying a childhood immunization schedule naturally tends to avoid extra doses of vaccines (i.e., minimizing cost and minimizing extraimmunization are often complementary objectives). Therefore, at present, GMCVFSP-which allows unrestricted extraimmunization because doing so might be economically favorable or required to satisfy the childhood immunization schedule-is an appropriate model for designing a minimum cost vaccine formulary. However, in the future, the biological risks and philosophical concerns associated with extraimmunization are likely to increase as more combination vaccines become available. In such an immunization environment, GLEVFSP will be the more appropriate model.
To simplify the formulation of GVFSP, recall that T dj = t ∈ T P djt = 1 is the set of time periods when vac-
n d , i = j, and hence for disease d ∈ D, the time window for vaccine dose j does not overlap with the time window for vaccine dose i for all i = j. Note that if every disease has mutually exclusive doses, then GVFSP simplifies to the following binary integer program (denoted by GVFSP-MED to signify the optimization model where each disease d ∈ D has mutually exclusive doses):
Constraint (1-MED) ensures that at least one vaccine that immunizes against disease d ∈ D is administered in some time period when dose j = 1 2 n d may be administered. Note that GVFSP-MED shares a similar structure with the Set-Multicover (MC) problem because each disease d ∈ D must be covered by at least n d vaccines (see Appendix 2 for a description of and references for MC). Specifically, without the time dimension, GVFSP-MED has the same structure as the Set-Covering (SC) problem. 
Computational Complexity
This section presents the computational complexity of GVFSP. Not surprisingly, in the worst case, this problem is intractable, although there are several special cases that are solvable in polynomial time.
Theorem 1. GVFSP is NP-hard in the strong sense.
Proof. Consider the following restricted instance of GVFSP:
The result follows from the fact that this restricted instance of GVFSP (i.e., GMCVFSP in this case) is an instance of GVFSP-MED (without the time dimension), and hence is an instance of SC (because n d = 1 for all d ∈ D), which itself is NP-hard in the strong sense (Karp 1972 , Garey and Johnson 1979 , Nemhauser and Wolsey 1999 .
The proof of Theorem 1 suggests several special cases of GVFSP that remain NP-hard in the strong sense. Furthermore, the restricted instance in the proof of Theorem 1 is an instance of GMCVFSP, and hence the following complexity results also hold for GMCVFSP. Specifically, GVFSP remains NP-hard in the strong sense when there exists only one time period (i.e., = 1), when the vaccine costs are all the same (i.e., K v = K for all vaccines v ∈ V ), and when each disease requires only one vaccine dose (i.e., n d = 1 for all diseases d ∈ D) because these special cases yield an instance of SC. Other special cases of GVFSP that are NPhard in the strong sense, which follow from SC, are when there exists only one vaccine (i.e., = 1 where
, when there exists at least three diseases (i.e., 3), or when every vaccine is at least a trivalent vaccine (i.e., Val v 3 for all vaccines v ∈ V ). Therefore, GVFSP remains NP-hard in the strong sense even when the sets T , D, and V , or when the dose
parameters are significantly restricted. Another facet to the complexity of GVFSP lies in the flexibility of the childhood immunization schedule. In general, GVFSP becomes more difficult if the vaccine doses for each disease may be administered in several time periods (i.e., for a given disease d ∈ D and vaccine dose j = 1 2 n d , P djt = 1 for multiple time periods t ∈ T ). Define a childhood immunization schedule as tight if every required vaccine dose for each disease d ∈ D may be administered in exactly one time period (i.e., for dose j = 1 2 n d and disease d ∈ D, P djt = 1 for exactly one time period t ∈ T ). By definition, a tight schedule is less flexible. A tight schedule also implies that all diseases d ∈ D have mutually exclusive doses because dose j = 1 2 n d may be administered in exactly one time period, and hence the time period t ∈ T when P djt = 1 is unique. Special cases of GVFSP that are polynomial time solvable occur when the valency of the vaccine set is limited to monovalent and bivalent vaccines, the schedule is tight, and the number of diseases is less than three. To see this, first consider limitations on the valency of the vaccine set. Lemma 1 considers the case when all vaccines v ∈ V are monovalents.
which is the minimum cost (economic and extraimmunization cost) of a vaccine v ∈ V that immunizes against disease d ∈ D. Therefore, the minimum cost to satisfy a childhood immunization schedule is given by d∈D d n d , and the optimal vaccine schedule can be found by iterating through the set of time periods and diseases, and administering dose j = 1 2 n d in the first time period when P djt = 1.
Given a tight childhood immunization schedule and a vaccine set composed of monovalent and bivalent vaccines, Lemma 2 yields a second polynomial time solvable special case of GVFSP.
Lemma 2. Given a tight childhood immunization schedule, if Val
Proof. The results follow immediately because a tight childhood immunization schedule yields SC problem instances, all of which are polynomial time solvable using a matching algorithm with O 2 complexity when Val v 2 (i.e., SC is polynomial time solvable when the cardinality of each subset in the collection of covering subsets is at most two; see Garey and Johnson 1979 and Kuhn 1955) .
From Lemmas 1 and 2, GVFSP is polynomial time solvable if the valency of the vaccine set is restricted and if the childhood immunization schedule is tight. Additionally, when = 1, GVFSP is polynomial time solvable (i.e., O time) because it is a special case of Lemma 1. GVFSP is also polynomial time solvable when = 2 using the dynamic programming algorithm presented in §4 because the subproblem solved at each stage of the dynamic program is an SC problem instance and all the vaccines must be monovalents and bivalents (Garey and Johnson 1979) .
Algorithms and Heuristics for GVFSP
Given that GVFSP is NP-hard in the strong sense, even when significantly restricting the cardinality of the input sets, it is likely that a significant amount of computing effort will be needed to find the optimal vaccine formulary for a given childhood immunization schedule. Clearly, exact algorithms that guarantee optimality do exist for GVFSP. However, unless P = NP, these algorithms will always have a worst case complexity that is exponential in the size of the inputs. Therefore, it is useful (and necessary) to design heuristics that do not guarantee optimality but execute in time that is polynomial in the size of the inputs. Section 4.1 presents an exact dynamic programming algorithm for GVFSP and §4.2 briefly discusses some heuristic approaches for GVFSP-MED that extend to a heuristic framework for GVFSP.
Dynamic Programming Algorithm
In §2, GVFSP is modeled as an integer programming problem, and hence can be solved using techniques like branch and bound (Nemhauser and Wolsey 1999) or dynamic programming (DP) (Bellman 1957) . This section presents and analyzes a DP algorithm for GVFSP.
The DP algorithm solves GVFSP one period at a time, beginning at the first time period (i.e., t = 1), and steps through each time period in T until t = . Therefore, the set T defines the stages of the DP algorithm. Define a state in the DP algorithm as the number of vaccine doses that have been administered for each disease through time period t ∈ T . Formally, a state in time period t ∈ T is a -dimensional vector S t = S t1 S t2 S t , where S td is the number of doses of a vaccine that have been administered for disease d = 1 2 , through time periods 1 2 t. Therefore, the state space in time period t ∈ T is t = S t ∈ Z m dt S td M dt for all d ∈ D . The decision in time period t ∈ T is which vaccines to administer that immunize against the diseases requiring vaccination in this time period (i.e., the binary decision variables X tv ) and is represented by the -dimensional binary vector
where B denotes the binary set 0 1 . These states and decisions define the DP algorithm system dynamics:
is also a binary vector. Furthermore, because Y t ∈ t is binary, it eliminates the need for the decision variables U dt , d ∈ D, t ∈ T because the vaccines administered in time period t ∈ T satisfy at most one dose requirement for a particular disease.
Given that Y t = S t − S t−1 , a transition from state S t−1 ∈ t−1 to state S t ∈ t requires that a dose of vaccine be administered in time period t ∈ T for each disease in the set
e., the set of vaccines that immunize against any disease that requires vaccination in time period t ∈ T ) and D t define a subinstance of GVFSP, where each such subinstance is a SC problem instance, termed SCP(Y t ), with base set D t and the collection of subsets V t . The specific SC problem instance for time period t ∈ T and decision Y t ∈ t is given by
To characterize the cost of decision Y t ∈ t , which is the cost of transitioning from state S t−1 ∈ t−1 in time period t − 1 ∈ T to state S t ∈ t in time period t ∈ T , define the one-period cost function C t S t−1 Y t as the cost of vaccination in time period t ∈ T given state S t−1 ∈ t−1 and decision Y t ∈ t . Note, however, that this one-period cost in time period t ∈ T depends only on decision Y t ∈ t , and hence the optimal value of SCP Y t = C t S t−1 Y t = C t Y t . Therefore, the optimal one-period cost over all possible decisions in time period t ∈ T is given by min
Define Z t S t as the minimum cost of a vaccine formulary that immunizes against all diseases through time period t ∈ T subject to the number of required vaccine doses at the end of time period t ∈ T being equal to S t ∈ t . Therefore, the DP optimality equation is given by the recurrence relation
Furthermore, the optimal cost of the vaccine formulary that satisfies a particular childhood immunization schedule is given by
where is the state space for the final time period ∈ T . The DP algorithm for GVFSP is now formally given.
Dynamic Programming Algorithm for GVFSP
Step 1. Initialize:
for each state S t ∈ t
Step 3. If t < , then t ← t + 1 and return to Step 2. Else, stop and return z * = min S ∈ Z S .
To determine the complexity of this DP algorithm, suppose that the SC problem instance with diseases and vaccines can be solved in O T SCP time. Furthermore, define S Max to be the maximum number of possible states within any time period t ∈ T . Each time period requires O S Max 2 · T SCP time, and hence with time periods, the DP algorithm for GVFSP executes in O S Max 2 · T SCP time. Because SC is NP-hard in the strong sense (Garey and Johnson 1979) , a pseudopolynomial algorithm is unlikely to exist unless P = NP. The DP algorithm's worst-case complexity could be improved, however, because each SC problem instance SCP Y t depends only on the decision vector Y t ∈ t . Therefore, the SC problem instance for decision Y t ∈ t needs only to be solved once. The complexity of solving for all possible decisions is O 2 because the maximum number of distinct SC problem instances that need to be solved is 2 , and the "For" loop (see the Set-Cover algorithm below) requires at most operations for a distinct SC problem instance. Therefore, for each time period t ∈ T , the complexity of Step 2 becomes O S Max 2 , and hence the DP algorithm has O S Max 2 + 2 worst-case time complexity, which is an improvement over O S Max 2 ·T SCP when S Max is large. To exploit this added efficiency, the implementation of the DP algorithm used for the computational analysis reported in §5 employs a branch-and-remember recursive algorithm to find the optimal cost for each SC problem instance SCP Y t . Therefore, SCP Y t need only be computed one time using the recursive algorithm Set-Cover. Initially, the given set of diseases for Y t is D t , and hence, D = D t .
Set-Cover D
If D = , then Return 0 If Set-Covering problem for D has been solved previously, then Return its optimal value Select a disease d ∈ D that requires immunization
Given a state S t in stage t, Step 2 of the DP algorithm requires that the recursion relation be computed for every state in stage t − 1 that is connected to S t . The naïve approach is to check every state S t−1 in stage t − 1. If S t − S t−1 is binary, then the two states are connected and the recurrence relation is computed. This approach is very inefficient for large problems because S t usually is connected to a small fraction of states in stage t − 1.
A more efficient approach is to use a combinatorial algorithm that generates only the states in stage t − 1 that are connected to S t ; the pseudocode for such an algorithm is provided below. The algorithm requires that the states can be retrieved from memory in an efficient manner. To accomplish this, the states for stage t are stored in a vector. The index of state S t in this vector is
To explain this indexing scheme, suppose that T is an enumeration tree for all the states in stage t, where level d in the tree (measured from the root) corresponds to disease d. The children of a node in level d correspond to the possible number of required doses that have been administered through time period t for disease d, namely, m dt m dt + 1 M dt . Therefore, the number of children of this node is M dt − m dt + 1. Consequently, the number of leaves in the subtree rooted at this node is
where there is a one-to-one correspondence between the leaves in T and the possible states in stage t. The full tree T does not need to be explicitly created and stored; only a vector corresponding to the leaves is needed. Furthermore, the leaf corresponding to state S t is given by
Note that for greater efficiency, before the DP algorithm is executed, d =d+1 M d t − m d t + 1 can be computed one time for all d ∈ D and t ∈ T .
Recursions S t
Let d = 1, best_cost = + , and
For greater efficiency, max(m d t−1 S td −1) and min(M d t−1 S td ) can be computed and stored before executing the while loop. Furthermore, the index needed to lookup Z t−1 S t − D can be computed incrementally during the while loop.
The DP algorithm offers several theoretical and computational advantages (in spite of its exponential worst-case complexity run time). First, the DP algorithm is efficient in practice with the 2006 Recommended Childhood Immunization Schedule because this schedule yields a reasonable state/decision space, and the SCP Y t instances in each time period t ∈ T are small (and, in many cases, are polynomial time solvable). Second, the DP algorithm offers insight into the theoretical structure of GVFSP. For example, the fact that the DP algorithm yields SC problem instances in each time period allows one to exploit both the theory and algorithms for SC and the time dimension of GVFSP. Third, the structure of the DP algorithm is ideal for solving partial childhood immunization schedules that arise when children have been partially immunized and then re-enter the health-care system to complete their immunization schedules (where the set of vaccines used to partially immunize the children are feasible initial solutions for the DP algorithm; this problem is termed the schedule completion problem. Note that if this set of vaccines is not feasible, then the recommended catch-up schedule would need to be used, which would require a completely new model formulation and analysis; see CDC 2006a for details of this catch-up schedule). Fourth, the structure of the DP algorithm makes it easier to capture restrictions that are schedule-specific by imposing such restrictions on each SCP Y t instance. Last, the structure of the DP algorithm is well suited for solving GVFSP-related problems that include some stochastic variation. For example, during a given time period t ∈ T , a parent/guardian may refuse a particular dose of vaccine if the number of injections required is unreasonably high. Therefore, as each vaccine is administered, the probability that a parent/guardian refuses another injection increases (this problem is termed the balking problem).
Heuristics for GVFSP
The worst-case complexity for the DP algorithm and other exact algorithm techniques suggests that there might be value in formulating heuristics that are computationally efficient and provide near-optimal solutions. This section briefly describes heuristics for GVFSP-MED and presents a heuristic framework for GVFSP. GVFSP-MED is first considered because of its simpler structure and its relation to the 2006 Recommended Childhood Immunization Schedule (all diseases have mutually exclusive doses). The heuristics for GVFSP-MED are also approximation algorithms, which by definition execute in polynomial time and provide an approximation bound on the objective function value of the heuristic solution (Hochbaum 1997) .
To discuss the heuristics for GVFSP-MED, some additional notation is needed. Define D = d j d ∈ D, j = 1 2 n d to be the set of all diseases ordered by dose, where D = d=1 n d . For all time periods t ∈ T and vaccines v ∈ V , define C tv = d j ∈ D I vd = 1 and P djt = 1 , which specifies the diseases and dose that vaccine v ∈ V immunizes against in time period t ∈ T . Therefore, C tv ⊆ D for all time periods t ∈ T and vaccines v ∈ V . Furthermore, in the case when all diseases d ∈ D have mutually exclusive doses, at most one d j ∈ D for all diseases d ∈ D is contained in any set C tv because, for a given disease d ∈ D and time period t ∈ T , P djt = 1 for at most one dose j = 1 2 n d , and hence each set C tv does not contain multiple doses for any disease d ∈ D. Furthermore, observe that the set D, together with the collection of sets C tv , t ∈ T , v ∈ V , define a SC problem instance. Moreover, the set C tv captures the usefulness of vaccine v ∈ V in time period t ∈ T , which provides a macro view of the time dimension within the SC problem instance (i.e., vaccine v ∈ V might be the optimal vaccine to administer in time period t ∈ T , but not in time period t ∈ T , depending on the doses permitted in each respective time period).
The transformation of GVFSP-MED into an SC problem instance implies that any SC problem heuristics may be applied to GVFSP-MED. Hochbaum (1997) and Bartholdi (1981) Bartholdi 1981) . Therefore, instead of rounding all variables greater than or equal to the 1/ threshold, it seems reasonable to round only a few variables with large fractional values because these variables are more likely to be one in the binary optimal solution. The MAX Rounding heuristic detailed in Hall (2006) limits the number of rounded variables by selecting the variables with the largest fractional values until a feasible integer solution is found. Bar-Yehuda and Even (1981) describe a linear time primal-dual approach that extends to the SC problem and supplies another -approximation algorithm for GVFSP-MED that does not require the solution of a linear program.
It is well known that an -approximation algorithm for the SC problem is a 2-approximation algorithm when every element to be covered lives in at most two subsets, due to the half-integrality property (see Nemhauser and Trotter 1975 Chvatal (1979) presents a greedy heuristic for SC and shows it to be an H -approximation algorithm, where is the maximum column sum of the constraint matrix and H is the sum of the first terms of the harmonic series (i.e., H = 1 + 1/2 + 1/3 + · · · + 1/ ). Clearly, this Greedy heuristic extends to GVFSP-MED by iteratively selecting the lowest cost available vaccine that immunizes against the most disease doses. The Greedy heuristic also has linear time complexity, and improves the approximation bound on the returned solution. For GVFSP-MED, = max t∈T v∈V C tv , and hence for an arbitrary childhood immunization schedule H , where = max t∈T v∈V C tv max v∈V Val v , will likely be much smaller than = max d∈D d . Observe that the values for H are reasonable for small values of max v∈V Val v . For example, H = 1, 3/2, and 11/6, when the vaccine set V is limited to monovalent, bivalent, and trivalent vaccines, respectively. See Hall (2006) for a more detailed description and analysis of the MAX Rounding, Primal Dual, and Greedy SC heuristics applied to GVFSP-MED.
Note that an SC problem heuristic for GVFSP-MED does not ensure a feasible solution for an arbitrary GVFSP instance, where some diseases d ∈ D in the childhood immunization schedule do not have mutually exclusive doses. The reason these heuristics do not ensure feasibility for an arbitrary GVFSP instance is because the sets C tv , for all time periods t ∈ T and vaccines v ∈ V , defined for the GVFSP-MED heuristics, no longer satisfy unique dose requirements because for the diseases d ∈ D that do not have mutually exclusive doses, there are time periods t ∈ T when more than one required dose may be administered. For example, if vaccine v ∈ V is a monovalent vaccine such that I vd = 1 for disease d ∈ D, and in time period t ∈ T , P djt = 1 0 for j = 1 2 3 4 n d , then C tv = d 1 d 2 , and hence administering vaccine v ∈ V in time period t ∈ T satisfies doses 1 and 2 for disease d. Therefore, to ensure that the sets C tv satisfy unique dose requirements, consider two variations of the set C tv for all time periods t ∈ T and vaccines v ∈ V :
(1) Minimum dose:
These variations ensure that set C tv (i.e., C tv = C MIN tv for all time periods t ∈ T and vaccines v ∈ V , or C tv = C MAX tv for all time periods t ∈ T and vaccines v ∈ V ) satisfies unique dose requirements for all diseases d ∈ D, and hence each variation results in a distinct GVFSP-MED instance.
Therefore, the A heuristic for GVFSP takes a GVFSP instance and defines two distinct GVFSP-MED instances, and executes the A heuristic for GVFSP-MED on each distinct GVFSP-MED instance, where A is the MAX Rounding, Greedy, or any other SC heuristic adapted to GVFSP-MED (see Hall 2006; Caprara et al. 1999 Caprara et al. , 2000 and Haddadi 1997) . The A heuristic is now formally given.
A Heuristic for GVFSP
Step 1. Select A ∈ {MAX Rounding or Greedy (or any other GVFSP-MED heuristic)}
Step 2. Initialize:
Step 3. Execute A heuristic for GVFSP-MED and return
Step 4. Initialize:
Step 5. Execute A heuristic for GVFSP-MED and return
Step 6 To describe this restriction, dose j = 1 2 n d is said to dominate vaccine dose k = 1 2 n d , j = k, for disease d ∈ D if P djt P dkt for all time periods t ∈ T . If disease d ∈ D has no dominant doses, then the time periods when vaccine dose j = 1 2 n d may be administered do not completely overlap with the time periods when vaccine dose k = 1 2 n d , j = k, may be administered, and hence for all j = 1 2 n d −1 , there exists time periods t t ∈ T such that P djt = 1 and P d j+1 t = 0 and P djt = 0 and P d j+1 t = 1. Therefore, for GVFSP, a restriction placed on the childhood immunization schedule is that for all diseases d ∈ D, vaccine dose j = 1 2 n d does not dominate vaccine dose k = 1 2 n d , j = k. All the diseases in the 2006 Recommended Childhood Immunization Schedule do not have a vaccine dose that dominates any other vaccine dose, and future schedules should also meet this restriction because there is a biological spacing requirement between each vaccine dose for every disease d ∈ D. This restriction ensures that every d j ∈ D (in Steps 2.a and 4.a) is contained in some set C tv for at least one time period t ∈ T and vaccine v ∈ V . Therefore, the A heuristic returns a feasible solution for GVFSP (assuming GVFSP has a feasible solution) because every iteration of the A heuristic for GVFSP-MED (in Step 3 and Step 5) administers a vaccine that satisfies at least one vaccine dose requirement for some disease d ∈ D (i.e., every iteration covers at least one (d j ∈ D). Note that the A heuristic for GVFSP-MED might optimally solve either (or both) distinct GVFSP-MED instance(s); however, this does not ensure that the resulting optimal solution is also optimal for the GVFSP instance because one GVFSP-MED instance always covers the minimum dose requirement while the other GVFSP-MED instance always covers the maximum dose requirement, and the optimal solution for the GVFSP instance may require the minimum dose in some cases and the maximum dose in other cases.
Computational Results
This section reports computational results comparing the MAX Rounding and Greedy heuristics and the DP algorithm presented in §4. These heuristics and algorithms are compared to an IP branch-and-bound (IP B&B) algorithm. Computational results are reported on three sets of test problems to demonstrate their computational effectiveness and limitations. All test problems in this section assume that d = 0 for all the diseases d ∈ D (i.e., the test problems are GMCVFSP instances; however, given the nearly identical structures of GMCVFSP and GVFSP, with the only difference being a single term in the objective function, the computational running times reported for GMCVFSP and those that would be obtained for GVFSP should be in the same order of magnitude). The first test problem is the 2006 Recommended Childhood Immunization Schedule. The second set of test problems are randomly generated based on hypothetical future childhood immunization schedules. The third set of test problems are larger, randomly generated childhood immunization schedules executed with several different vaccine sets. The size of these randomly generated childhood immunization schedules assume that the future Recommended Childhood Immunization Schedules will expand to include more diseases and time periods, and hence will require a larger number of both monovalent and combination vaccines, which appears to be the case given recent trends in expanding the schedule. For example, four time periods and three diseases have been added to the Recommended Childhood Immunization Schedule since 1995, and there are currently several new vaccine products being marketed and tested for use in children (see CDC 1995 , Cochi 2005 , and Infectious Diseases in Children 2002 .
For each heuristic, the solution quality effectiveness measure = Z Heuristic /Z * is reported, where Z Heuristic is the objective function cost returned by the heuristic and Z * is the optimal objective function cost (returned by the exact algorithms). The execution time (in CPU seconds) is also reported for each heuristic and exact algorithm, which is the efficiency effectiveness measure. For the 2006 Recommended Childhood Immunization Schedule (the first test problem; see Figure 1 ), all heuristics and exact algorithms were coded and executed in MATLAB v7.0 on a 2.4-MHz Pentium IV with 1 GB of RAM including the IP B&B algorithm (using default settings) from MATLAB's optimization toolbox. For the randomly generated childhood immunization schedules (i.e., the second and third set of test problems), the DP algorithm was coded and executed in C and the IP formulation was solved using CPLEXv9.1, both on a 2.7-MHz Pentium IV with 512 MB of RAM.
For the 2006 Recommended Childhood Immunization Schedule, D = {1 = hepatitis B, 2 = diphtheriatetanus-pertussis, 3 = Haemophilus influenzae type b, 4 = polio, 5 = measles-mumps-rubella, 6 = varicella, 7 = pneumococcus, 8 = influenza, 9 = hepatitis A} with dose vector n = 3 5 4 4 2 1 4 5 2 because diphtheria, tetanus, and pertussis and measles, mumps, and rubella are each considered one disease, and T = 1 2 10 . The vaccine set is V = 1 = 1 2 = 2 3 = 3 4 = 4 5 = 5 6 = 6 7 = 7 8 = 8 9 = 9 10 = 2 3 11 = 1 3 12 = 1 2 4 . The parameters I vd are indicated by the set V . For example, vaccine 1 is the monovalent vaccine for disease 1 (hepatitis B) and vaccine 12 is the combination vaccine Pediarix ® that immunizes against diseases 1 (hepatitis B), 2 (diphtheria-tetanus-pertussis), and 4 (polio). The schedule parameters P djt , Q dt , and m dt for diseases d ∈ D, dose j = 1 2 n d , and time periods t ∈ T are all obtained from Figure 1 . For example, for disease d = 1 = hepatitis B and dose j = 2, P djt = 1 (0) for time periods t = 2 3 1 4 5 6 7 8 9 10 . In the case of influenza (disease 8), it is not necessary to require three additional time periods as described in §2 because vaccine 8 is a monovalent vaccine, is the only vaccine that immunizes against influenza, and is the only vaccine required in these additional time periods. Therefore, determining the optimal cost and schedule to satisfy the required doses for Influenza is trivial. Three different cost scenarios are evaluated. The first scenario considers only the actual purchase price of the vaccines. In particular, the cost vector c = 9 00 12 75 7 66 10 42 16 67 52 25 54 12 9 71 12 10 24 62 24 50 38 34 , where c v , v = 1 2 12, is the federal contract purchase price (in US $) for vaccine v ∈ V (CDC Vaccine Price List 2005). The second scenario includes the purchase price of the vaccine and a fixed injection cost of $10/injection. The third scenario includes the purchase price, the fixed injection cost, and a preparation cost of $3/injection. Table 1 reports (for each scenario) the objective function cost Z and the execution time for each heuristic and exact algorithm. Table 1 also reports the solution quality effectiveness measure for each heuristic.
Lemma 1 implies that GMCVFSP is polynomial time solvable when all vaccines v ∈ V are monovalent vaccines, and hence the results reported in Table 1 for Scenario 1 are not surprising, given that most vaccines v ∈ V are monovalent. In fact, the combination vaccines are not competitively priced when considering purchase price alone. The fixed costs considered in Scenarios 2 and 3 penalize the monovalent vaccines and make the combination vaccines more economical. For example, the purchase prices for monovalent vaccines 1, 2, and 4 sum to $32.17, which is less than the $38.34 purchase price for the combination vaccine Pediarix ® (i.e., v = 12). However, in Scenario 2, the total cost of the combination vaccine Pediarix ® is $48.34, whereas the total costs for monovalent vaccines 1, 2, and 4 sum to $62.17. Observe that the observed optimality gap (i.e., ) for the heuristics was significantly better than the worst-case optimality gap of = 6 for the MAX Rounding heuristic and H = 1 83 for the Greedy heuristic. Furthermore, the exact algorithms were very efficient when executed in MATLAB.
The second set of test problems considers hypothetical future childhood immunization schedules. To better measure the efficiency of the exact algorithms, the DP was coded and executed in C and the IP formulation was solved using CPLEX v9.1. The DP algorithm and CPLEX were executed on 45 randomly generated childhood immunization schedules with 15 time periods, 75 vaccines, and 12 diseases. Therefore, each random childhood immunization schedule reflects a gradual expansion in the sets D (from 9 to 12 diseases) and T (from 10 to 15 time periods) and a significant increase in the number of available vaccines, particularly, combination vaccines. To generate a random childhood immunization schedule, the schedule was divided into n uniform blocks. The number of time periods in the time window (i.e., T dj = t ∈ T P djt = 1 for d ∈ D, j = 1 2 n d ) for dose 1 for every disease was randomly assigned and then randomly placed in the first block of time periods. Similarly, the number of time periods in the time window for dose 2 for every disease requiring a second dose was randomly assigned and then randomly placed in the second block of time periods with possible overlap with the last time period from the first block. This process was repeated until all time windows were scheduled. Therefore, in each random childhood immunization schedule, 1 n d n = 5 for all disease d ∈ D and P djt = 1 for at most three time periods t ∈ T for every disease d ∈ D and dose j = 1 2 Table 2 reports the average and the standard deviation for the execution time (in CPU seconds) averaged over the 45 random childhood immunization schedules. CPLEX (on average) required significantly more execution time than the DP algorithm (by at least one order of magnitude). Furthermore, the DP algorithm showed far less variability in its execution time.
The third set of test problems considers larger, randomly generated childhood immunization schedules that demonstrate the effect of combination vaccines and further demonstrate how the schedule's size affects the efficiency and solution quality of each heuristic and exact algorithm. Each heuristic and exact algorithm were executed on 30 randomly generated childhood immunization schedules with 24 time periods, 100 vaccines, and 17 diseases such that 1 n d 6 for all diseases d ∈ D, and P djt = 1 for at most four time periods t ∈ T for every dis-
For each randomly generated childhood immunization schedule, each heuristic and exact algorithm was executed five times, where in execution i = 1 2 5, Val v i + 2 for all vaccines v ∈ V . Table 3 reports, for each heuristic, algorithm, and valency, the execution time (in CPU seconds), and the value for averaged across all 30 randomly generated childhood immunization schedules. The overall average and standard deviation across all vaccine sets is also reported for each heuristic and exact algorithm as well as the relative LP-IP gap = Z IP /Z LP , where Z IP (Z LP is the optimal objective function cost for the IP (LP relaxation).
The values reported in Table 3 show that in most cases, the execution time required to optimally solve GMCVFSP steadily increased as the valency of the vaccine set increased, while the execution times for the heuristics decreased as the valency of the vaccine set increased. For example, when Val v 3 for all vaccines v ∈ V , both heuristics were outperformed by CPLEX. However, when Val v 7 for all vaccines v ∈ V , the least efficient heuristic, MAX Rounding, was approximately three times faster than the (most efficient exact) DP algorithm. Note that the heuristics would perform even more efficiently if implemented using a high-level programming language such as C or C++. As expected, the heuristic solution quality deteriorated as the valency of the vaccine set increased; however, the Greedy heuristic outperformed the MAX Rounding heuristic in solution quality and efficiency, which is not surprising because the Greedy heuristic does not require the solution of an LP and is less sensitive to the LP-IP gap. Observe, however, that the heuristics' solution quality was significantly better than the worst-case optimality gap of 4 for the MAX Rounding heuristic and H 1 83 for the Greedy heuristic. The observed decrease in execution time for the heuristics is intuitive because each heuristic should require fewer iterations when the vaccines are able to protect against more diseases. For the higher valencies, the DP algorithm significantly outperformed CPLEX (by two orders of magnitude for Val v 7). The data reported in Tables 1-3 all suggest that the DP algorithm provides an efficient exact algorithm for GVFSP even for hypothetical future childhood immunization schedules where most of the vaccines are combination vaccines. Furthermore, on average, the DP algorithm requires significantly less computational effort to find the optimal solution than is required by the IP B&B algorithm and with less variability. As shown in §4, the computational complexity of the DP algorithm is highly sensitive to the number of diseases because the decision space is bounded above by 2 and S Max also depends on the number of diseases. On the other hand, the computational complexity of the IP B&B algorithm is highly sensitive to the number of decision variables because the number of possible branches is bounded above by 2 (where there are binary decision variables in an instance of GVFSP). Furthermore, the computational effort of an IP B&B algorithm is sensitive to the gap between the cost of the optimal integer solution and the corresponding cost of the optimal LP relaxation solution because a large gap would tend to require more branching to find the optimal integer solution (Nemhauser and Wolsey 1999) . Note that one could use any of the heuristics to produce an initial solution for the IP B&B algorithm, which might improve its computational run time for some of these problem instances.
The values reported in Tables 1-3 provide empirical support for these observations and remarks. For example, the DP algorithm was always more efficient than the IP B&B algorithm except in Table 3 when Val v 3 and = 17, and the execution time using CPLEX was the largest when the average relative LP-IP gap was 1.06. Therefore, it is reasonable to conjecture that the DP algorithm will be more efficient for childhood immunization schedules when the number of diseases remains relatively small (e.g., < 20), and the IP B&B algorithm will be more efficient for childhood immunization schedules when the number of diseases is large (e.g., 20) and the number of time periods and vaccines remains reasonable (e.g., < 1 500). Note that these bounds for and are based on empirical observation of the exact algorithms. The observed difference in execution time between the heuristics and exact algorithms reported in Table 3 could be problematic for childhood immunization schedules with a large disease set (e.g., 20) or for other practical uses. For example, the heuristics would enable a more efficient analysis of studies where GVFSP is a subproblem, which would then require the solution of several (even thousands or tens of thousands) GVFSP instances-for example, analysis of the balking problem (as noted in §4.1), or the research reported in Jacobson and Sewell (2002) , where thousands of childhood immunization schedules are used in a Monte Carlo simulation to determine a price distribution for potential combination vaccines. Furthermore, Jacobson et al. (2007) suggest that advances in biotechnology will likely lead to individualized vaccines, and hence each child's vaccination requirements will be considered on a case-by-case basis. Likewise, the flexibility in considering different cost definitions for the cost parameters K v (or c v , v ∈ V , or different sets of vaccines V will make it possible to analyze the economics associated with satisfying a given childhood immunization schedule from several different perspectives (e.g., vaccine manufacturers, federal and state health agencies, health-care practitioners, and parents all having different economic priorities and perspectives). Such flexibility implies several unique instances of GVFSP (even for a fixed childhood immunization schedule). Therefore, GVFSP might need to be solved for each child, on a case-by-case basis, or for several different cost scenarios, and hence more efficient algorithms might be needed to provide practical value for the public health community.
Analysis of GVFSP
This section briefly discusses alternative solution techniques for GVFSP and computationally examines the tradeoff between the two separate objectives of minimizing economic cost and minimizing extraimmunization as a function of the weight placed on extraimmunization.
It can be shown that a solution resulting from the DP in §4 will be an efficient (Pareto optimal) solution for GVFSP, but additional analysis is required to determine the entire Pareto efficient frontier because the feasible set is nonconvex (Ehrgott 2005 
the resulting total amount of extraimmunization might still depend on the order in which the upper bounds were determined. Clearly, such a process is computationally intensive, although doing so might offer insights into what diseases (or vaccines) are contributing the most extraimmunization, which is indeed valuable information. Moreover, these constraints add an additional level of complexity to the problem. For example, each state in the DP algorithm would need to include both the number of required doses and the amount of extraimmunization for each disease. This added dimension would cause an explosion in the size of the state space, which limits the practicality of the DP algorithm. Furthermore, the feasibility of the heuristics would no longer be guaranteed, and additional checks for feasibility would be required at every iteration of the heuristic. Work is in progress to further analyze this model and to identify alternative algorithms, both exact and heuristic. Therefore, modeling extraimmunization as a cost (as done in GVFSP) rather than a constraint is a reasonable alternative.
As discussed in §2, GMCVFSP implicitly limits extraimmunization because extra doses incur an economic cost, and combination vaccines (using federal contract purchase prices) cost more than the sum of the corresponding monovalent vaccines for the same diseases. Therefore, if the set of vaccines V contains monovalent vaccines for all diseases in D, extraimmunization is unlikely. In fact, the optimal solution in §5 for test problem 1 (i.e., the 2006 Recommended Childhood Immunization Schedule displayed in Figure 1 ) under Scenario 1 does not include the use of any combination vaccine, and hence no extraimmunization exists. In Scenarios 2 and 3 of test problem 1, the combination vaccines are more competitively priced, and combination vaccines 10 and 12 are part of the optimal solutions. Furthermore, no extraimmunization exists in these solutions. However, in the future, as more combination vaccines gain FDA approval and become more economically competitive with monovalent vaccines, thereby making monovalent vaccines obsolete, the amount of extraimmunization is likely to increase or extraimmunization will be required to satisfy the given childhood immunization schedule. For example, recall from Figure 1 that D = {1 = hepatitis B, 2 = diphtheria-tetanus-pertussis, 3 = Haemophilus influenzae type b, 4 = polio, 5 = measles-mumps-rubella, 6 = varicella, 7 = pneumococcus, 8 = influenza, 9 = hepatitis A} and consider the vaccine set V = 1 = 1 3 2 = 2 3 3 = 1 2 4 4 = 2 3 4 5 = 5 6 6 = 7 7 = 8 8 = 9 . Therefore, in this set V , monovalent vaccines are replaced with their corresponding currently licensed combination vaccines. 8. Observe that extraimmunization is required to satisfy the childhood immunization schedule in Figure 1 using the vaccines in V (e.g., vaccine 1 = 1 3 or vaccine 3 = 1 2 4 must be administered in time period t = 1 to satisfy dose 1 for hepatitis B, where either case incurs extraimmunization). Solving GMCVFSP for this problem instance yields an optimal solution that requires 10 doses of extraimmunization (one extra dose for hepatitis B, three extra doses for diphtheria-tetanus-pertussis, four extra doses for Haemophilus influenzae type b, one extra dose for polio, and one extra dose for varicella). Note that the extraimmunization for diphtheria-tetanus-pertussis, which is particularly worrisome because there might be some biological risks associated with this extraimmunization. Using GVFSP to model the childhood immunization schedule in Figure 1 provides a mechanism to limit the amount of extraimmunization for diphtheria-tetanus-pertussis. For example, let d = 1 0 for d = 2 1 3 4 5 6 7 8 9 . Then, K = 35 31 26 36 60 50 10 15 , where the vth component of vector K represents K v , v = 1 2 8, and hence using any vaccine that immunizes against diphtheria-tetanuspertussis becomes slightly more costly. However, solving GVFSP for this problem instance yields the same optimal solution provided by GMCVFSP above. Clearly, the weight d = 1 for d = 2 is not sufficiently large to eliminate extraimmunization for diphtheria-tetanus-pertussis. Therefore, letting d = 10 0 for d = 2 1 3 4 5 6 7 8 9 , which yields K = 35 40 35 45 60 50 10 15 , and solving GVFSP for this problem instance yields an optimal solution that requires five doses of extraimmunization (three extra doses for hepatitis B, one extra doses for Haemophilus influenzae type b, and one extra dose for varicella). Moreover, extraimmunization for diphtheria-tetanuspertussis is entirely eliminated (although the economic cost for this solution is higher).
To further analyze the trade-off between minimizing cost and minimizing extraimmunization, the DP algorithm in §4 in GVFSP was executed on the third set of test problems described in §5 for multiple values of , where d = for all d ∈ D. Specifically, each test problem was executed for = 0, 2 i , i = 0 1 2 8. Recall that the third set of test problems described in §5 comprised several different vaccine sets V , where the valency increased from three up to seven, and hence the vaccine sets consisted of combination vaccines, which means that extraimmunization was needed in most cases to ensure that the childhood immunization schedule was satisfied. extraimmunization often incurs an economic penalty. To further distinguish reasons for extraimmunization, say that nondiscretionary extraimmunization occurs to ensure that the childhood immunization schedule is satisfied, while discretionary extraimmunization occurs only because there exists an economic advantage over other combination vaccines that may incur less extraimmunization. Figures 2  and 3 show that, even for the randomly generated childhood immunization schedules with all combination vaccines, discretionary extraimmunization is minimal (<5% reduction as → ). Clearly, these results assume that extraimmunization is equally weighted for all diseases, which is unlikely in practice.
Conclusion and Research Extensions
This paper introduces GVFSP, which seeks a vaccine formulary that minimizes a weighted sum of the cost to fully immunize a child and the amount of extraimmunization for a generic childhood immunization schedule. Special cases of GVFSP (GMCVFSP and GLEVFSP) were also presented to illustrate the issues of economic cost and extraimmunization as separate objective functions. As more combination vaccines come to market and the Recommended Childhood Immunization Schedule becomes more complex to include more diseases and cover more time periods, GVFSP captures the combinatorial explosion of alternatives and choices for public health policy makers, vaccine manufacturers, pediatricians, and parents/guardians. In general, GVFSP was shown to be NP-hard (in the strong sense) unless the vaccines, the schedule parameters, or the disease set are significantly restricted. Therefore, the existence of an algorithm that finds a minimum cost schedule in polynomial time is unlikely, unless P = NP. This paper presents a DP algorithm that solves GVFSP to optimality but becomes intractable as the size of the childhood immunization schedule grows, particularly as the size of the disease set grows. However, this DP algorithm is computationally compared to an IP branch-andbound algorithm (MATLAB and CPLEX), and the results obtained show that the DP algorithm significantly outperforms the IP branch-and-bound algorithm and remains efficient when the size of the disease set is reasonable. As expected, for larger randomly generated childhood immunization schedules, the DP and CPLEX require more time to execute when compared to the heuristics presented in §4, but the DP algorithm is the algorithm of choice because it is both computationally efficient and exact. The heuristics, however, might enable more efficient analysis of larger future childhood immunization schedules and practical analysis involving Monte Carlo simulation, finding an optimal vaccine formulary for each child, on a case-by-case basis, or for several different cost scenarios, which might require the solution of several unique GVFSP instances. Section 6 discusses alternative solution techniques for GVFSP and computationally examines the trade-off between the two separate objectives of minimizing economic cost and minimizing extraimmunization as a function of the weight placed on extraimmunization. The results show that GVFSP provides a robust model to address concerns with extraimmunization whereas GMCVFSP does not. The results obtained also suggest that high penalties for extraimmunization might have a limited effect in reducing extraimmunization, given the need to satisfy the childhood immunization schedule; however, these results assumed the limited use of monovalent vaccines and that extraimmunization is equally weighted for all diseases. Therefore, these results provide support for focusing the analysis on GMCVFSP, where schedule requirements and direct costs implicitly limit extraimmunization levels, and GVFSP, which explicitly limits extraimmunization levels disease by disease.
Work is in progress to further extend the results reported. First, there are several extensions that could be added to reflect some of the real-world constraints on the cost of vaccinating a child. For example, including a fixed cost for each clinic visit (such as insurance co-pays that a parent/guardian pays at each visit) in the objective function, including relational constraints on the vaccine set such as brand matching requirements (i.e., if manufacturer A's vaccine is administered for disease d ∈ D, dose j, then all subsequent doses for disease d ∈ D must also use manufacturer A's vaccine), or using different cost definitions for the vaccine set such as using private-sector vaccine prices. Alternative objective functions or cost parameters might also be considered, such as minimizing the number of injections in each time period or minimizing the number of time periods required to satisfy the childhood immunization schedule. Next, the structure of the DP algorithm is well suited for adding uncertainty (like that described for the balking problem in §4.1) to GVFSP. Such GVFSP extensions would add significant practical value for the pediatric public health community. The approximation bounds for the heuristics for GVFSP-MED do not apply to the solution returned by the A heuristic for GVFSP because the A heuristic for GVFSP converts a GVFSP instance into two distinct GVFSP-MED instances; work is in progress to determine approximation bounds for the A heuristic for GVFSP. Furthermore, improving the existing heuristics and their associated approximation bounds, and exploring nonapproximability results for GVFSP are also of practical and theoretical interest.
Appendix 1 Background on Infectious Diseases
Infectious diseases have plagued humankind for centuries. Even as recently as the early 20th century, infectious disease was the leading worldwide killer (Cohen 2000) . For example, in 1900, the average life expectancy at birth in the United States was 47 years, with nearly 30% of all deaths caused by infectious disease. Moreover, roughly one in ten children died before the age of four due to infectious diseases (Cohen 2000) .
By the end of the 20th century, the life expectancy in the United States increased to over 76 years (National Vital Statistics Reports 2004) . Naturally, it is worth considering why life expectancy in this country has nearly doubled over the past century. According to the World Health Organization (WHO), vaccinations and clean water have had the greatest impact on world health (Plotkin and Orenstein 2004) . As evidence to this claim, the United States has witnessed a 100% decrease in the number of cases of indigenous poliomyelitis and a 99% decrease in the number of cases of diphtheria, measles, mumps, and rubella since vaccines became available. Furthermore, in 1966, there were an estimated 20 million cases of smallpox worldwide, and because of vaccination, the WHO declared the eradication of this disease in 1980 (Mackay and Rosen 2001) . Today many health-care professionals still regard the eradication of smallpox as one of the greatest accomplishments of public health (Cohen 2000, Mackay and Rosen 2001) .
In spite of this progress against infectious disease, much work still remains. For example, in 1998, almost a quarter of the deaths worldwide (over 13 million of the 54 million deaths) were caused by infectious disease (Cohen 2000) . Unfortunately, an estimated 1 million of these deaths were attributed to measles alone-a disease with a readily available vaccine at a relatively inexpensive cost of US $15 per dose (Cohen 2000, Plotkin and Orenstein 2004) . The emergence of new infectious diseases such as human immunodeficiency virus (HIV) and Lyme disease, the resurgence of diseases such as tuberculosis, and the recent threat of bioterrorism (anthrax, smallpox, etc.) highlight the need for continued vigilance in the effort to combat infectious diseases (Binder et al. 1999, Plotkin and Orenstein 2004) . Centers for Disease Control and Prevention, for his efforts in providing the authors with the original problem being addressed here, his assistance with obtaining appropriate data in support of the models and analysis, and his long-standing encouragement and feedback on this line of research. His input on this work has been invaluable and appreciated. The authors gratefully acknowledge Udatta Palekar, College of Business, University of Illinois at Urbana-Champaign, for noting an error in the original formulation of GVFSP. Finally, the authors thank the special issue editors, Stefanos Zenios and Edwin Romeijn, the associate editor, and four anonymous referees for their insightful comments and suggestions that resulted in a significantly improved manuscript. This research was supported in part by the National Science Foundation (grants DMI-0457176 and DMI-0456945). The second author was also supported in part by the Air Force Office of Scientific Research (FA9550-07-1-0232). The views expressed in this paper are those of the authors and do not reflect the official policy or position of the United States Air Force, Department of Defense, National Science Foundation, or the United States Government.
